Exelixis, Inc. Stock News

Exelixis, Inc. ( EXEL ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:30 AM EST Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division Welcome to this next fireside chat with E...

Exelixis is positioned for growth with positive phase 3 data for zanzalintinib in metastatic colorectal cancer, following cabozantinib's success. STELLAR-303 results show modest survival benefit but introduce the first immunotherapy approach in refractory mCRC, despite notable toxicity concerns. EXEL's pipeline strength is buoyed by zanzalintinib, but real-world adoption and broader success rem...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Monday, November 10 in Boston. Stifel 2025 Healthcare Conference: Exelixis is sched...

Exelixis, Inc. ( EXEL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Susan Hubbard - Executive Vice President of Public Affairs & Investor Relations Michael Morrissey - CEO, President & Director Christopher Senner - Executive VP & CFO Dana Aftab - Executive Vice President of Research & Development P. Haley - Executive Vice President of Commercial Conference Call Parti...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “In the third quarter of 2025, Exelixis gained momentum in the cabozantinib franchise and delivered on critical strategi...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Inter...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the study met one of i...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) originating in the lungs or thymus. These data will be presented at the 2025 European Society for Medical Oncology Congres...